ClinVar Miner

Submissions for variant NM_000551.3(VHL):c.191G>C (p.Arg64Pro) (rs104893826)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000132356 SCV000187445 pathogenic Hereditary cancer-predisposing syndrome 2019-04-17 criteria provided, single submitter clinical testing Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation;Other strong data supporting pathogenic classification;In silico models in agreement (deleterious) and/or completely conserved position in appropriate species;Confirmed de novo alteration in the setting of a new disease (appropriate phenotype) in the family
Division of Genomic Diagnostics,The Children's Hospital of Philadelphia RCV000208872 SCV000264666 pathogenic Von Hippel-Lindau syndrome 2018-08-01 criteria provided, single submitter clinical testing
Invitae RCV000475973 SCV000553379 pathogenic Erythrocytosis, familial, 2; Von Hippel-Lindau syndrome 2018-12-10 criteria provided, single submitter clinical testing This sequence change replaces arginine with proline at codon 64 of the VHL protein (p.Arg64Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is not present in population databases (rs104893826, ExAC no frequency). This variant has been reported to segregate with Von Hippel-Lindau (VHL) syndrome in several families (PMID: 9663592, 19336503, 17661816), was found as de novo in an individual with pheochromocytoma (PMID: 24555745) and in an unrelated individual with pheochromocytoma (PMID: 17102083). In one family, 2 individuals carrying this variant presented with no typical VHL manifestations after annual clinical monitoring at ages 40 and 59 (PMID: 17661816), suggesting reduced penetrance of this variant. ClinVar contains an entry for this variant (Variation ID: 2226). Experimental studies in vitro show conflicting results concerning the effect this missense change has on the ability of VHL to degrade HIF2 alpha (PMID: 16452184, 11331612, 15611064), but indicate that this variant results in impaired binding to and ubiquitination of HIF1 alpha compared to wild-type VHL (PMID: 15611064, 11331612).  Different studies using different assays also report conflicting results as to whether or not this variant affects the ability of VHL to bind fibronectin and assemble a distinguishable fibronectin matrix (PMID: 11331612, 16452184). However, renal carcinoma cells containing this variant were shown to be capable of inducing relatively late-onset, vascularized and invasive renal cell tumors with aberrant extracellular matrices in a nude mouse xenograft assay, while cells containing wild-type VHL did not induce tumors (PMID: 16452184). For these reasons, this variant has been classified as Pathogenic.
PreventionGenetics,PreventionGenetics RCV000679019 SCV000805324 likely pathogenic not provided 2018-02-13 criteria provided, single submitter clinical testing
OMIM RCV000002314 SCV000022472 pathogenic Pheochromocytoma 1998-07-29 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.